Indonesian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
International Journal of Cardiology 2016-Mar

Incidence and risk factors for severe renal impairment after first diagnosis of heart failure: A cohort and nested case-control study in UK general practice.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Tautan disimpan ke clipboard
Alexander Michel
Mar Martín-Pérez
Ana Ruigómez
Luis A García Rodríguez

Kata kunci

Abstrak

OBJECTIVE

We aimed to evaluate the incidence, time-course and risk factors for severe renal impairment (SRI) among incident heart failure (HF) patients.

RESULTS

Patients aged 1-89years from 2000 to 2005 with incident HF and without SRI or cancer (N=18,049) were identified from The Health Improvement Network (a primary care database representative of the UK population). Patients with a first ever record of SRI during follow-up were identified and eligible non-cases used as controls (N=5377; mean age 74years). Cohort and nested case-control analyses were conducted to identify risk factors for SRI. 2818 patients (15.6%, mean age 75years) in the HF cohort developed SRI over a mean of 2.84years with incidence highest in the first year following HF diagnosis. Hazard ratios (HRs) with 95% confidence intervals (CIs) were as follows: diabetes (1.96, 1.80-2.14), hypertension (1.23, 1.14-1.33), peripheral artery disease (1.29, 1.15-1.45), ischemic cerebrovascular disease (1.14, 1.03-1.26), and anemia (1.19, 1.06-1.34). Several cardiovascular medications were associated with SRI in the case-control analysis, odds ratios (95% CIs): 5.07 (3.87-6.64) for all diuretics, 3.22 (2.83-3.66) for potassium-sparing diuretics, 2.40 (1.96-2.93) for thiazide and related diuretics and 3.27 (2.67-4.01) for loop-diuretics.

CONCLUSIONS

SRI is a frequent complication in patients with newly diagnosed HF. Comorbidities may contribute to its development and should be adequately treated. Robust clinical trial data on beneficial or possibly deleterious effects of diuretics, especially loop-diuretics and potassium-sparing diuretics, on SRI development in HF patients are warranted.

Bergabunglah dengan
halaman facebook kami

Database tanaman obat terlengkap yang didukung oleh sains

  • Bekerja dalam 55 bahasa
  • Pengobatan herbal didukung oleh sains
  • Pengenalan herbal melalui gambar
  • Peta GPS interaktif - beri tag herba di lokasi (segera hadir)
  • Baca publikasi ilmiah yang terkait dengan pencarian Anda
  • Cari tanaman obat berdasarkan efeknya
  • Atur minat Anda dan ikuti perkembangan berita, uji klinis, dan paten

Ketikkan gejala atau penyakit dan baca tentang jamu yang mungkin membantu, ketik jamu dan lihat penyakit dan gejala yang digunakan untuk melawannya.
* Semua informasi didasarkan pada penelitian ilmiah yang dipublikasikan

Google Play badgeApp Store badge